Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader
Journal of Medicinal Chemistry · 24.10.2024 · 67 (20) · 18247-18264
DOI: 10.1021/acs.jmedchem.4c01596 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.10.2024. Verfasst von Licheng Zhou und 18 weiteren Autor:innen. Beteiligte Einrichtung: International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MO…. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinases, Antineoplastic Agents, Biological Availability, Proteolysis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Howard Hughes Medical Institute, National Cancer Institute.
Abstract (Originalsprache)
Selective degradation of cyclin-dependent kinases 12 and 13 (CDK12/13) emerges as a new potential therapeutic approach for triple-negative breast cancer (TNBC) and other human cancers. While several proteolysis-targeting chimera (PROTAC) degraders of CDK12/13 were reported, none are orally bioavailable. Here, we report the discovery of ZLC491 as a potent, selective, and orally bioavailable CDK12/13 PROTAC degrader. The compound effectively degraded CDK12 and CDK13 with DC50 values of 32 and 28 nM, respectively, in TNBC MDA-MB-231 cells. Global proteomic assessment and mechanistic studies revealed that ZLC491 selectively induced CDK12/13 degradation in a cereblon- and proteasome-dependent manner. Furthermore, the molecule efficiently suppressed transcription and expression of long genes, predominantly a subset of genes associated with DNA damage response, and significantly inhibited proliferation of multiple TNBC cell lines. Importantly, ZLC491 achieved an oral bioavailability of 46.8% in rats and demonstrated potent in vivo degradative effects on CDK12/13 in an MDA-MB-231 xenografted mouse model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Developme…
- State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Rd., Shanghai 200032, China.
- University of Chinese Academy of Sciences, No. 1 Yanxihu Road, Huairou District, Beijing 101408, China.
- Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109, United States.
- School of Life Science and Technology, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.
ORCID-Profile: Fengtao Zhou, Zhen Wang, Ke Ding
Förderung
- NCI NIH HHS
- Howard Hughes Medical Institute
- National Cancer Institute
- National Key Research and Development Program of China
- Shenzhen Bay Laboratory
- American Cancer Society
- National Natural Science Foundation of China
- Prostate Cancer Foundation
Zitieren
APA
Zhou, L., Zhou, K., Chang, Y., Yang, J., Fan, B., Su, Y., Li, Z., Mannan, R., Mahapatra, S., Ding, M., Zhou, F., Huang, W., Ren, X., Xu, J., Wang, G. X., Zhang, J., Wang, Z., Chinnaiyan, A. M., & Ding, K. (2024). Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader. Journal of Medicinal Chemistry, 67(20), 18247-18264. https://doi.org/10.1021/acs.jmedchem.4c01596
Vancouver
Zhou L, Zhou K, Chang Y, Yang J, Fan B, Su Y, et al. Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader. Journal of Medicinal Chemistry. 2024;67(20):18247-18264. doi:10.1021/acs.jmedchem.4c01596
BibTeX
@article{Zhou2024,
author = {Zhou, Licheng and Zhou, Kaijie and Chang, Yu and Yang, Jianzhang and Fan, Bohai and Su, Yuhan and Li, Zilu and Mannan, Rahul and Mahapatra, Somnath and Ding, Ming and Zhou, Fengtao and Huang, Weixue and Ren, Xiaomei and Xu, Jian and Wang, George Xiaoju and Zhang, Jinwei and Wang, Zhen and Chinnaiyan, Arul M and Ding, Ke},
title = {Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {20},
pages = {18247--18264},
doi = {10.1021/acs.jmedchem.4c01596}
}
EUVIMED